Patents by Inventor Gregory J. Hannon
Gregory J. Hannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102010Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: August 4, 2023Publication date: March 28, 2024Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 11753641Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: February 8, 2021Date of Patent: September 12, 2023Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20210254064Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: February 8, 2021Publication date: August 19, 2021Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20200048633Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: May 6, 2019Publication date: February 13, 2020Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 10329562Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: March 6, 2017Date of Patent: June 25, 2019Assignee: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20170342410Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: March 6, 2017Publication date: November 30, 2017Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 9624494Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: February 24, 2015Date of Patent: April 18, 2017Assignee: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 9132152Abstract: The present disclosure provides a method of generating an induced pluripotent stem cell; as well as nucleic acids and genetically modified host cells useful in generating iPSCs. The present disclosure provides iPSCs, and methods of use of same.Type: GrantFiled: February 9, 2012Date of Patent: September 15, 2015Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Lin He, Yong Jin Choi, Chao-Po Lin, Gregory J. Hannon, Xingyue He
-
Publication number: 20150197749Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: February 24, 2015Publication date: July 16, 2015Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 8993532Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: GrantFiled: April 22, 2011Date of Patent: March 31, 2015Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Sihem Cheloufi
-
Publication number: 20150057164Abstract: Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions.Type: ApplicationFiled: November 5, 2014Publication date: February 26, 2015Inventors: Christof FELLMANN, Scott W. LOWE, Gregory J. HANNON, Johannes Ekkehart ZUBER
-
Patent number: 8901288Abstract: Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions.Type: GrantFiled: October 24, 2008Date of Patent: December 2, 2014Assignee: Cold Spring Harbor LaboratoryInventors: Christof Fellmann, Scott W. Lowe, Gregory J. Hannon, Johannes E. Zuber
-
Patent number: 8829264Abstract: The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: GrantFiled: June 18, 2012Date of Patent: September 9, 2014Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Patrick Paddison, Emily Bernstein, Amy Caudy, Douglas Conklin, Scott Hammond
-
Patent number: 8753811Abstract: The present invention provides methods of making a population of nucleic acid molecules, wherein each nucleic acid molecule comprises a predetermined nucleic acid sequence, each of said methods comprising the steps of: (a) synthesizing, on a substrate, a population of nucleic acid molecules wherein: i) each synthesized nucleic acid molecule comprises a predetermined nucleic acid sequence; and ii) each synthesized nucleic acid molecule is localized to a defined area of said substrate; (b) harvesting said population of synthesized nucleic acid molecules from said substrate to yield harvested nucleic acid molecules; and (c) introducing said harvested nucleic acid molecules into vector molecules.Type: GrantFiled: February 16, 2012Date of Patent: June 17, 2014Assignee: Cold Spring Harbor LaboratoryInventors: Stephen H. Friend, Michele A. Cleary, Ernest M. Coffey, Kristopher A. Killian, Gregory J. Hannon, Patrick Paddison
-
Publication number: 20130276158Abstract: The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: ApplicationFiled: June 18, 2012Publication date: October 17, 2013Applicant: Cold Spring Harbor LaboratoryInventors: Gregory J. HANNON, Patrick Paddison, Emily Bernstein, Amy Caudy, Douglas Conklin, Scott Hammond
-
Publication number: 20130179999Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.Type: ApplicationFiled: April 22, 2011Publication date: July 11, 2013Applicant: COLD SPRING HARBOR LABORATORYInventors: Gregory J. Hannon, Sihem Cheloufi
-
Patent number: 8426675Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.Type: GrantFiled: June 7, 2011Date of Patent: April 23, 2013Assignee: Cold Spring Harbor LaboratoryInventors: Ross Dickins, Scott W. Lowe, Gregory J. Hannon
-
Patent number: 8407012Abstract: Methods and systems of DNA sequencing that compensate for sources of noise in next-generation DNA sequencers are described.Type: GrantFiled: July 6, 2009Date of Patent: March 26, 2013Assignee: Cold Spring Harbor LaboratoryInventors: Yaniv Erlich, Partha Pratim Mitra, Gregory J. Hannon
-
Patent number: 8399248Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.Type: GrantFiled: May 5, 2008Date of Patent: March 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
-
Patent number: 8383599Abstract: The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: GrantFiled: May 16, 2008Date of Patent: February 26, 2013Assignee: Cold Spring Harbor LaboratoryInventors: Gregory J. Hannon, Patrick J. Paddison, Emily Bernstein, Amy Caudy, Douglas S. Conklin, Scott Hammond